TOKYO, Japan I July 30, 2015 I Nippon Kayaku Co., Ltd. (Head Office: Tokyo; President: Masanobu Suzuki; hereafter referred to as “Nippon Kayaku”) today announced that global Phase 3 clinical trial program for CT-P6 which is developing jointly with Celltrion, Inc. (Head Office: Incheon, South Korea; Co-representative: HyoungKi.Kim，WooSung.Kee) will be extended to Japan by Nippon Kayaku expertise.
CT-P6 is a biosimilar of the Trastuzumab monoclonal antibody that has played an important role in treatment of Metastatic Breast Cancer, Early Stage Breast Cancer and Gastric Cancer with over-expression of HER2 gene. Nippon Kayaku began development of this biosimilar in November 2010 following the conclusion of a cooperation agreement with Celltrion, Inc. and Celltrion Healthcare Co., Ltd. (Head Office: Incheon, South Korea; CEO: SeungSuh.Hong).
CT-P6 is the second monoclonal antibody biosimilar for Nippon Kayaku following Infliximab BS for I.V. Infusion 100mg 「NK」, which was marketed last year. In the field of Breast Cancer, Nippon Kayaku is currently conducting Phase 3 Clinical Trial Program for NK105. With the goal of early launch of these products, we expect to make an even greater contribution to Cancer patients, their families and medical professionals.
[Reference material – Profile of Celltrion, Inc.]
| Company name |
Celltrion, Inc. |
| Location |
Incheon, South Korea |
| Listed on |
KOSDAQ |
| Business areas |
This company was established in 2002 in a special economic zone in Incheon, South Korea. It has expanded its business and is now one of the leading bio-pharmaceutical companies in Korea. It has developed advanced bio-pharmaceutical production technologies, and quickly began operating its own commercial plant. Its product pipeline includes RemsimaTM, the world’s first biosimilar monoclonal antibody, several other biosimilars and new molecular entities.
Celltrion Healthcare Co., Ltd is the company which possesses exclusive global distribution and marketing rights for all Celltrion, Inc. products. |
| Link |
http://www.celltrion.com/ |
SOURCE: Nippon Kayaku
Post Views: 207
TOKYO, Japan I July 30, 2015 I Nippon Kayaku Co., Ltd. (Head Office: Tokyo; President: Masanobu Suzuki; hereafter referred to as “Nippon Kayaku”) today announced that global Phase 3 clinical trial program for CT-P6 which is developing jointly with Celltrion, Inc. (Head Office: Incheon, South Korea; Co-representative: HyoungKi.Kim，WooSung.Kee) will be extended to Japan by Nippon Kayaku expertise.
CT-P6 is a biosimilar of the Trastuzumab monoclonal antibody that has played an important role in treatment of Metastatic Breast Cancer, Early Stage Breast Cancer and Gastric Cancer with over-expression of HER2 gene. Nippon Kayaku began development of this biosimilar in November 2010 following the conclusion of a cooperation agreement with Celltrion, Inc. and Celltrion Healthcare Co., Ltd. (Head Office: Incheon, South Korea; CEO: SeungSuh.Hong).
CT-P6 is the second monoclonal antibody biosimilar for Nippon Kayaku following Infliximab BS for I.V. Infusion 100mg 「NK」, which was marketed last year. In the field of Breast Cancer, Nippon Kayaku is currently conducting Phase 3 Clinical Trial Program for NK105. With the goal of early launch of these products, we expect to make an even greater contribution to Cancer patients, their families and medical professionals.
[Reference material – Profile of Celltrion, Inc.]
| Company name |
Celltrion, Inc. |
| Location |
Incheon, South Korea |
| Listed on |
KOSDAQ |
| Business areas |
This company was established in 2002 in a special economic zone in Incheon, South Korea. It has expanded its business and is now one of the leading bio-pharmaceutical companies in Korea. It has developed advanced bio-pharmaceutical production technologies, and quickly began operating its own commercial plant. Its product pipeline includes RemsimaTM, the world’s first biosimilar monoclonal antibody, several other biosimilars and new molecular entities.
Celltrion Healthcare Co., Ltd is the company which possesses exclusive global distribution and marketing rights for all Celltrion, Inc. products. |
| Link |
http://www.celltrion.com/ |
SOURCE: Nippon Kayaku
Post Views: 207
